These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12885234)

  • 21. Protease inhibitors. Part 2. Weakly basic thrombin inhibitors incorporating sulfonyl-aminoguanidine moieties as S1 anchoring groups: synthesis and structure-activity correlations.
    Clare BW; Scozzafava A; Briganti F; Iorga B; Supuran CT
    J Enzyme Inhib; 2000; 15(3):235-64. PubMed ID: 10811030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template.
    Jhoti H; Cleasby A; Reid S; Thomas PJ; Weir M; Wonacott A
    Biochemistry; 1999 Jun; 38(25):7969-77. PubMed ID: 10387040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The methyl group of N(alpha)(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage.
    Friedrich R; Steinmetzer T; Huber R; Stürzebecher J; Bode W
    J Mol Biol; 2002 Mar; 316(4):869-74. PubMed ID: 11884127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions.
    Olsen J; Seiler P; Wagner B; Fischer H; Tschopp T; Obst-Sander U; Banner DW; Kansy M; Müller K; Diederich F
    Org Biomol Chem; 2004 May; 2(9):1339-52. PubMed ID: 15105924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies.
    Weir MP; Bethell SS; Cleasby A; Campbell CJ; Dennis RJ; Dix CJ; Finch H; Jhoti H; Mooney CJ; Patel S; Tang CM; Ward M; Wonacott AJ; Wharton CW
    Biochemistry; 1998 May; 37(19):6645-57. PubMed ID: 9578548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin.
    Greenidge PA; Mérette SA; Beck R; Dodson G; Goodwin CA; Scully MF; Spencer J; Weiser J; Deadman JJ
    J Med Chem; 2003 Apr; 46(8):1293-305. PubMed ID: 12672230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxyanion-mediated inhibition of serine proteases.
    Presnell SR; Patil GS; Mura C; Jude KM; Conley JM; Bertrand JA; Kam CM; Powers JC; Williams LD
    Biochemistry; 1998 Dec; 37(48):17068-81. PubMed ID: 9836602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives.
    Thorstensson F; Kvarnström I; Musil D; Nilsson I; Samuelsson B
    J Med Chem; 2003 Mar; 46(7):1165-79. PubMed ID: 12646027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors.
    Wagner J; Kallen J; Ehrhardt C; Evenou JP; Wagner D
    J Med Chem; 1998 Sep; 41(19):3664-74. PubMed ID: 9733491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs.
    Hanessian S; Therrien E; Zhang J; Otterlo Wv; Xue Y; Gustafsson D; Nilsson I; Fjellström O
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5429-32. PubMed ID: 19674897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protease inhibitors, part 13: Specific, weakly basic thrombin inhibitors incorporating sulfonyl dicyandiamide moieties in their structure.
    Clare BW; Scozzafava A; Supuran CT
    J Enzyme Inhib; 2001 Jan; 16(1):1-13. PubMed ID: 11496831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel non-covalent thrombin inhibitors incorporating P(1) 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics.
    Marinko P; Krbavcic A; Mlinsek G; Solmajer T; Bakija AT; Stegnar M; Stojan J; Kikelj D
    Eur J Med Chem; 2004 Mar; 39(3):257-65. PubMed ID: 15051174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position.
    Obreza A; Stegnar M; Urleb U
    Pharmazie; 2004 Sep; 59(9):659-67. PubMed ID: 15497744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protease inhibitors: Part 4. Synthesis of weakly basic thrombin inhibitors incorporating pyridinium-sulfanilylaminoguanidine moieties.
    Supuran CT; Briganti F; Scozzafava A; Ilies MA
    J Enzyme Inhib; 2000; 15(4):335-56. PubMed ID: 10995066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multipolar interactions in the D pocket of thrombin: large differences between tricyclic imide and lactam inhibitors.
    Schweizer E; Hoffmann-Röder A; Olsen JA; Seiler P; Obst-Sander U; Wagner B; Kansy M; Banner DW; Diederich F
    Org Biomol Chem; 2006 Jun; 4(12):2364-75. PubMed ID: 16763681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
    Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
    J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
    Lazarova TI; Jin L; Rynkiewicz M; Gorga JC; Bibbins F; Meyers HV; Babine R; Strickler J
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5022-7. PubMed ID: 16876411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.
    Supuran CT; Scozzafava A; Briganti F; Clare BW
    J Med Chem; 2000 May; 43(9):1793-806. PubMed ID: 10794696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090.
    Malley MF; Tabernero L; Chang CY; Ohringer SL; Roberts DG; Das J; Sack JS
    Protein Sci; 1996 Feb; 5(2):221-8. PubMed ID: 8745399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.